During the first quarter of 2019, Samsung Bioepis’ biosimilars revenue increased to $175 million, up from $128 million in the first quarter of 2018. Those numbers, say Biogen, are driven by the launch of biosimilar adalimumab, Imraldi.
During the first quarter of 2019, Samsung Bioepis’ biosimilars revenue increased to $175 million, up from $128 million in the first quarter of 2018. Those numbers, say Biogen, are driven by the launch of biosimilar adalimumab, Imraldi.
Biogen, which together with its partner Samsung BioLogics forms Samsung Bioepis, reported its first quarter 2019 financial results on April 24.
The partnership has 3 biosimilars that are currently in the marketplace: a biosimilar etanercept (Benepali) referencing Enbrel; Imraldi, referencing Humira; and a biosimilar infliximab, sold as Flixabi in the European Union and as Renflexis in the United States, referencing Remicade.
Benepali sales were up 3% year over year, for a total of $124 million in revenue. Flixabi was up 123% year over year, for $15 million in revenue. Imraldi, which was launched in October 2018, was up 114% quarter over quarter, for $36 million in revenue.
These numbers come after reports that biosimilar adalimumab in general—and Imraldi in particular—are off to a strong start in Europe. IQVIA data released in the first quarter of the year show that in Germany, which had the most biosimilar adalimumab options available in November 2018, the greatest percentages of patients who switched from Humira to another option were transitioned to Imraldi (37%). Sandoz’s Hyrimoz and Amgen’s Amgevita trailed behind at 15% and 12%, respectively.
In the United Kingdom, which was responsible for the most consumption of brand-name Humira in the European Union as of September 2018, Imraldi was awarded 45% of the market via a centralized tender. Amgevita and Sandoz were each awarded roughly one-fourth of the market, and Mylan’s Hulio was awarded approximately 5% of the market.
According to IQVIA, “It is Samsung with Imraldi that has won out so far in the 2 markets that matter the most: Samsung has the largest potential market in the United Kingdom and has shown the most success in acquiring Humira patients in Germany.”
Samsung Bioepis continues to develop other biosimilar agents; currently in the drug maker’s pipeline are FDA- and European Medicines Agency—approved trastuzumab biosimilar Ontruzant, a bevacizumab biosimilar undergoing a phase 3 study, a ranibizumab biosimilar undergoing a phase 3 study, and an eculizumab biosimilar currently in phase 1 clinical trials.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.